Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

NCT05983432 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT05983432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 8, 2023
Completion date
July 22, 2030
Enrollment
540 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, esophageal cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, non small cell lung cancer, ovarian cancer, prostate adenocarcinoma, small cell lung cancer, triple negative breast cancer